Online citations, reference lists, and bibliographies.
← Back to Search

Microsomal Metabolism Of The 5-lipoxygenase Inhibitor L-739,010: Evidence For Furan Bioactivation.

K. Zhang, J. A. Naue, B. Arison, K. Vyas
Published 1996 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
The novel 5-lipoxygenase inhibitor [1S,5R]-3-cyano-1-(3-furyl)-6-(6-[3-(3 alpha-hydroxy-6,8-dioxabicyclo[3.2.1]octanyl)]pyridin-2-yl- methoxyl)naphthalene (L-739,010), when administered to rats and rhesus monkeys, was found to produce metabolites which appeared to be covalently bound to plasma proteins. Incubation of [14C]L-739,010 with rat liver microsomes did not yield appreciable amounts of soluble metabolites but resulted in covalent binding to microsomal proteins. The covalent binding was NADPH-dependent and was enhanced by 1.5- and 2-fold in liver microsomes from rats, pretreated with phenobarbital and dexamethasone, respectively. Addition of triacetyloleandomycin and diethyldithiocarbamate to the incubation mixture inhibited the covalent binding by 60% and 46%, respectively. These findings suggest that the cytochrome P450 3A family of enzymes play an important role in the bioactivation of L-739,010. The presence of GSH attenuated the covalent binding by 50%, while methoxylamine, an aldehyde trapping agent, blocked the covalent binding completely and, concurrently, produced several soluble metabolic adducts. Subsequently, major methoxylamine adducts were identified by LC-MS/MS and NMR as O-methyloximes of the ring-opened furan moiety of L-739,010. Incubation of L-739,010 with methoxylamine and hepatic microsomes from dog, rhesus monkey, and human produced similar metabolic adducts as those formed by rat liver microsomes. Therefore, under these experimental conditions, the furan moiety, which undergoes oxidative cleavage to the highly reactive 2-butene-1,4-dialdehyde, represents the major site of L-739,010 biotransformation. This putative reactive intermediate could react with microsomal proteins in vitro and physiological proteins in vivo. Since furan bioactivation is believed to be responsible for the toxicity of many furan-containing compounds, the furan moiety of L-739,010 may be regarded as undesirable.



This paper is referenced by
10.1007/978-1-0716-1542-3_19
Cytochrome P450-Mediated Drug Bioactivation Assay: An Untargeted High Resolution Accurate Mass LC/MS Assay
Kevin M. Johnson (2021)
10.1021/acs.jmedchem.1c00790
Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design.
Yong Wu (2021)
10.1002/AJOC.201700418
Cu(TFA)2‐Catalyzed Picolinamido‐Directed C(sp2)−H Cyanation of Naphthalenes by Using Benzoyl Cyanide as a Cyano Source
He Song (2017)
A 674 Toni Lassila IN VITRO METHODS IN THE STUDY OF REACTIVE DRUG METABOLITES WITH LIQUID CHROMATOGRAPHY / MASS SPECTROMETRY
S. Palviainen (2016)
10.1080/03602532.2016.1195404
Biotransformation and bioactivation reactions – 2015 literature highlights
T. Baillie (2016)
In vitro methods in the study of reactive drug metabolites with liquid chromatography / mass spectrometry
Toni Lassila (2016)
Synthesis of nordihydroguaiaretic acid (NDGA) analogues and their oxidative metabolism
I. Asiamah (2015)
10.1016/j.toxrep.2015.07.002
Comparison of trapping profiles between d-peptides and glutathione in the identification of reactive metabolites
J. Laine (2015)
10.1021/tx500212c
Identification and mitigation of a reactive metabolite liability associated with aminoimidazoles.
A. Srivastava (2014)
10.1124/dmd.114.058222
Metabolism of Diosbulbin B In Vitro and In Vivo in Rats: Formation of Reactive Metabolites and Human Enzymes Involved
Baohua Yang (2014)
10.1021/tx3003824
Reactive metabolites in the biotransformation of molecules containing a furan ring.
L. Peterson (2013)
10.1002/9780470921920.EDM053
Drug Bioactivation and Oxidative Stress
Hayley M. Webb (2012)
10.1016/J.APSB.2012.02.010
LC-MS-based metabolomics in profiling of drug metabolism and bioactivation
F. Li (2012)
10.1002/9780470921920.EDM052
Identification of Drug Metabolites
S. Obach (2012)
10.1002/9780470921920.EDM113
Bioactivation and Reactive Metabolite Assays
W. Tang (2012)
10.1002/9780470921920.EDM072
Bioactivation I: Bioactivation by Cytochrome P450s
D. Dalvie (2012)
10.1002/9783527655748.CH5
Pathways of Reactive Metabolite Formation with Toxicophores/‐Structural Alerts
A. Kalgutkar (2012)
10.1002/mas.20316
Enhancement of the capabilities of liquid chromatography-mass spectrometry with derivatization: general principles and applications.
Fengguo Xu (2011)
10.1002/9780470929278.CH3
Metabolic Activation of Organic Functional Groups Utilized in Medicinal Chemistry
A. Kalgutkar (2011)
10.1016/B978-0-12-381290-2.00001-X
Designing drugs to avoid toxicity.
G. Smith (2011)
10.1002/JLCR.1829
Synthesis of [13C5] and [carbonyl‐14C]‐5‐chlorofuran‐2‐carboxylic acid
P. Dorff (2011)
10.1016/j.tiv.2010.11.002
D-Isomer of gly-tyr-pro-cys-pro-his-pro peptide: a novel and sensitive in vitro trapping agent to detect reactive metabolites by electrospray mass spectrometry.
J. Laine (2011)
10.1021/tx200033v
Profiling the reactive metabolites of xenobiotics using metabolomic technologies.
F. Li (2011)
10.2174/138920011795202974
Conventional and novel approaches in generating and characterization of reactive intermediates from drugs/drug candidates.
H. Orhan (2011)
10.1016/j.bmcl.2009.10.130
Antiplasmodial activity of piperazine sulfonamides.
Derek C. Martyn (2010)
10.1021/tx100268g
Metabolism and toxicity of menthofuran in rat liver slices and in rats.
S. C. Khojasteh (2010)
10.1016/j.vascn.2009.10.005
Quantitative assessment of the metabolic activation of alicyclic amines via aldehyde.
M. Miura (2010)
10.1002/9780470571224.PSE122
Chemical Mechanisms in Toxicology
M. Grillo (2010)
10.1002/9780470890387.CH7
Strategies for the Detection of Reactive Intermediates in Drug Discovery and Development
M. Grillo (2010)
10.4155/bio.09.32
From known knowns to known unknowns: predicting in vivo drug metabolites.
O. Pelkonen (2009)
10.1016/j.drudis.2008.11.002
Liquid chromatography-mass spectrometry in in vitro drug metabolite screening.
A. Tolonen (2009)
10.1002/rcm.3953
Rapid detection and characterization of reactive drug metabolites in vitro using several isotope-labeled trapping agents and ultra-performance liquid chromatography/time-of-flight mass spectrometry.
Timo Rousu (2009)
See more
Semantic Scholar Logo Some data provided by SemanticScholar